Join the Melanoma group to help and get support from people like you.
Melanoma News (Page 3)
Related terms: Cancer, Melanoma, Malignant Melanoma, Skin Cancer, Melanoma
Common PFAS Chemicals Linked to Cancers in Women
TUESDAY, Sept. 19, 2023 – Harmful "forever" chemicals are widespread in the environment, and new research hints they pose a particular health risk to women. A new study suggests women who are...
Former 'Real Housewife' Teddi Mellencamp Reveals Another Melanoma Diagnosis
THURSDAY, Sept. 14, 2023 – Reality TV star and wellness coach Teddi Mellencamp announced on Instagram Wednesday that she has been diagnosed with yet another melanoma. This is Mellencamp’s 12th or 1...
In Situ, Invasive Melanoma Diagnoses Decreased in 2020
THURSDAY, Sept. 7, 2023 – During 2020, there were decreases seen for in situ and invasive melanoma diagnoses, according to a research letter published online Sept. 6 in JAMA Dermatology. Daniel Y....
Reinforced Learning Model Can Improve Sensitivity of Skin Cancer Diagnosis
WEDNESDAY, Aug. 9, 2023 – Incorporating human preferences into an image-based diagnostic algorithm can improve artificial intelligence (AI)-based decision support, according to a study published...
Vitamin D Might Ease the Agony of Psoriasis
TUESDAY, July 25, 2023 – People who have psoriasis may want to get their vitamin D levels checked. New research suggests that blood levels of the so-called "sunshine vitamin" may affect the severity...
Melanoma Presentation, Mortality Varies by Race
MONDAY, July 24, 2023 – Patterns of melanoma presentation, disease severity, and mortality vary by race, according to a research letter published online July 11 in the Journal of the American...
FDA Approves Opdualag (nivolumab and relatlimab-rmbw) for the Treatment of Patients with Unresectable or Metastatic Melanoma
PRINCETON, N.J.--(BUSINESS WIRE)-- March 18, 2022 – Bristol Myers Squibb (NYSE: BMY) today announced that Opdualag (nivolumab and relatlimab-rmbw),anew, first-in-class,fixed-dose combination of...
FDA Approves Genentech’s Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma
South San Francisco, CA – July 30, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq...
FDA Approves Keytruda (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
KENILWORTH, N.J.--(BUSINESS WIRE) February 19, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Mektovi (binimetinib) and Braftovi (encorafenib) in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (Braftovi and Mektovi, Array BioPharma Inc.) in combination for patients with unresectable or metastatic...
Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations
BOULDER, Colo., June 27, 2018 /PRNewswire/ – Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi capsules in combination with...
Novartis Receives FDA Approval of Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanoma
:Basel, April 30, 2018 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant t...
Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
PRINCETON, N.J.--(BUSINESS WIRE) March 6, 2018 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License...
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease
PRINCETON, N.J.--(BUSINESS WIRE)-- December 20, 2017 Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection...
FDA Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
PRINCETON, N.J.--(BUSINESS WIRE) July 24, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy...
Ask a question
To post your own question to this support group, sign in or create an account.